Integrated Biopharma Inc financial data

Symbol
INBP on OTC
Location
225 Long Avenue, Building 15, Hillside, NJ
Fiscal year end
June 30
Latest financial report
Sep 23, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 354 % +25.3%
Quick Ratio 200 % +11.5%
Debt-to-equity 28 % -29.1%
Return On Equity 4.04 % +582%
Return On Assets 3.16 % +643%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 31.1M shares +3.19%
Common Stock, Shares, Outstanding 31.1M shares +3.19%
Entity Public Float 3.11M USD -7.6%
Common Stock, Value, Issued 62K USD +3.33%
Weighted Average Number of Shares Outstanding, Basic 30.3M shares +0.76%
Weighted Average Number of Shares Outstanding, Diluted 31.2M shares +0.96%

Income Statement

Label TTM Value / Value Unit Change %
Operating Income (Loss) 2.02M USD +705%
Nonoperating Income (Expense) 39K USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 2.06M USD +669%
Income Tax Expense (Benefit) 1.25M USD +704%
Net Income (Loss) Attributable to Parent 808K USD +621%
Earnings Per Share, Basic 0 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.62M USD +116%
Accounts Receivable, after Allowance for Credit Loss, Current 5.43M USD +16.3%
Inventory, Net 9.36M USD -16.7%
Other Assets, Current 356K USD +24.5%
Assets, Current 18.8M USD +4.97%
Deferred Income Tax Assets, Net 3.34M USD -27.5%
Property, Plant and Equipment, Net 1.72M USD -4.38%
Operating Lease, Right-of-Use Asset 855K USD -52.2%
Assets 24.9M USD -4.98%
Accounts Payable, Current 2.27M USD -9.68%
Liabilities, Current 4.25M USD -30.6%
Operating Lease, Liability, Noncurrent 221K USD -73.9%
Liabilities 4.58M USD -34.2%
Retained Earnings (Accumulated Deficit) -31.4M USD +2.51%
Stockholders' Equity Attributable to Parent 20.3M USD +5.61%
Liabilities and Equity 24.9M USD -4.98%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 657K USD -50%
Net Cash Provided by (Used in) Financing Activities -7K USD -333%
Net Cash Provided by (Used in) Investing Activities -56K USD -47.4%
Common Stock, Shares Authorized 50M shares 0%
Common Stock, Shares, Issued 31.1M shares +3.19%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 594K USD -53.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 12K USD +20%
Deferred Tax Assets, Valuation Allowance 1.78M USD +39.7%
Operating Lease, Liability 1.32M USD
Depreciation 318K USD +3.58%
Payments to Acquire Property, Plant, and Equipment 56K USD +47.4%
Lessee, Operating Lease, Liability, to be Paid 1.4M USD
Property, Plant and Equipment, Gross 9.91M USD +2.16%
Operating Lease, Liability, Current 634K USD -32.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 169K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 661K USD
Deferred Income Tax Expense (Benefit) 197K USD +2363%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 77K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 64K USD
Deferred Tax Assets, Operating Loss Carryforwards 4.37M USD -13.2%
Deferred Federal Income Tax Expense (Benefit) 1.39M USD +1018%
Operating Lease, Payments 236K USD -10.9%
Additional Paid in Capital 51.8M USD +0.52%
Depreciation, Depletion and Amortization 88K USD +14.3%
Deferred State and Local Income Tax Expense (Benefit) -150K USD -15100%
Interest Expense 52K USD 0%